top of page
Public Statements
Every statement CANN has issued — press releases, public comments filed with federal and state agencies, and fact sheets — collected in one searchable archive. Use the filters to browse by year, topic, or document type.
Public comments and testimony are part of how CANN does policy work in public. We file them, archive them, and make them accessible because the record matters.
On The Record
Our ten most recent public comments and press releases. Search the full document archive below for everything else.
Public Comments
Document Title | Document Summary | Publication Date |
|---|---|---|
CANN Public Comment: Maryland PDAB Upper Payment Limit Clarification (September 2026) | CANN urges the Maryland PDAB to clarify how upper payment limits will avoid financial harm to pharmacies under COMAR 14.01.06.02, and opposes any reduction to the 60-day public comment period for drug cost review studies. | 09/22/2026 |
CANN Public Comment: Washington PDAB Ongoing Review Concerns (September 2026) | CANN urges the Washington PDAB to address process and data concerns in its ongoing drug review cycle, arguing that upper payment limits are ineffective affordability tools that risk adverse outcomes for patients, pharmacies, and 340B-covered entities. | 09/14/2026 |
CANN Public Comment: FDA Advisory Committee on GRAIL Galleri Multi-Cancer Early Detection Test (September 2026) | CANN urges the FDA Advisory Committee to grant full consideration and Premarket Approval to GRAIL's Galleri multi-cancer early detection test, highlighting the disproportionate cancer burden on people with HIV/AIDS, including anal cancer (20–25x higher risk), non-Hodgkin lymphoma, and cervical cancer. | 09/08/2026 |
CANN Public Comment: Senate HELP Committee 340B Drug Pricing Integrity and Affordability for Patients Act Discussion Draft (August 2026) | CANN urges the Senate HELP Committee to strengthen the 340B Drug Pricing Integrity and Affordability for Patients Act draft by requiring measurable patient outcomes, tightening 318 sub-grantee oversight, limiting contract pharmacy fees, expanding transparency reporting to all covered entities, and mandating patient savings disclosures. | 08/28/2026 |
CANN Public Comment: Biosimilar Red Tape Elimination Act (S. 1954) — Request to Preserve State Frameworks (June 2026) | CANN opposes S. 1954 as drafted, arguing that automatic biosimilar interchangeability deeming undermines the FDA-backed standard on which all 51 state pharmacy substitution frameworks rely, and urges the Senate HELP Committee to add a rule-of-construction provision preserving state biosimilar substitution authority before the June 17, 2026 markup. | 06/16/2026 |
CANN Public Comment: Washington PDAB UPL Rulemaking Draft (June 2026) | CANN submits comments on Washington's proposed UPL rulemaking (WAC 182-52-0010 and 182-52-0100), raising concerns about vague definitions of "excess costs," conflicting UPL scope language, inconsistent methodology standards, and appeals processes that disrupt the physician-patient relationship. | 06/16/2026 |
CANN Public Comment: 340B Rebate Model — House Appropriations Committee (June 2026) | CANN supports a rebate-based model for 340B transactions, arguing it enhances transparency, reduces duplicate discounts and diversion, and improves program integrity, while citing ADAPs as a proven "Gold Standard" and pushing back on DSH-system concerns. | 06/09/2026 |
CANN Written Comment: Maryland PDAB Cost Review Study Process Revisions (June 2026) | Comment to the Maryland PDAB on proposed amendments to COMAR 14.01.04 Cost Review Study Process, addressing the MCDB ERISA data blind spot, MDPN/IRA inclusion criteria, the risk that foreign data introduces QALY-based methods prohibited by the ADA, and the need for greater patient-centered focus. | 06/01/2026 |
CANN Written Comment: Maryland PDAB Ongoing Board Developments (May 2026) | Written comment to the Maryland PDAB on patient outreach concerns, the Board's mixed Farxiga (no UPL) and Jardiance (proposed UPL) decisions, and the moral and ethical concerns of testing UPL implementation on state mental health facilities and university health plans. | 05/12/2026 |
CANN Public Comment: Colorado PDAB Ongoing Board Activity (May 2026) | CANN raises questions about Colorado's PDAB ongoing board activity, focusing on HB23-1225 drug eligibility thresholds, the effectiveness of upper payment limits for patient out-of-pocket affordability, formulary protection gaps, and patient engagement via the PDAAC toolkit and Community Partner Network. | 05/11/2026 |
Press Releases
Document Title | Document Summary | Publication Date |
|---|---|---|
CANN Statement on Introduction of the SUSTAIN 340B Act (August 2026) | CANN's CEO Jen Laws and 340B Policy Director Kalvin Pugh respond to the SUSTAIN 340B Act, criticizing its data clearinghouse user-fee model and failure to center patient interests, while praising its child site provisions as the strongest element of current federal 340B reform proposals. | 08/05/2026 |
CANN Statement on HRSA's Revised 340B Rebate Model Pilot Program (August 2026) | Jen Laws, President & CEO of CANN, responds to HRSA's revised 340B Rebate Model Pilot Program, arguing it incentivizes covered entity compliance, addresses duplicate discounts, and moves HRSA toward active oversight — drawing on ADAP rebate model experience. | 08/04/2026 |
CANN Statement on the Introduction of the SECURE 340B Act (July 2026) | Jen Laws, President & CEO of CANN, responds to the SECURE 340B Act, supporting patient benefit and transparency provisions while opposing the proposed clearinghouse in favor of a rebate model and calling for a clearer patient definition and child site language. | 07/06/2026 |
CANN Statement on Minnesota Department of Health 340B Covered Entity Report (June 2026) | Jen Laws responds to Minnesota's February 2026 340B Covered Entity Report, finding MN covered entities earned $1.34 billion in net 340B revenue in 2024 — more than double 2023 — while safety-net clinics received less than 1%, calling for federal oversight to match the scale of the problem. | 06/16/2026 |
CANN Statement on Iowa's $22 Million 340B Contract Pharmacy Scandal (April 2026) | Jen Laws responds to Iowa's ADAP crisis caused by NuCara Specialty Pharmacy withholding $22M in 340B savings, forcing a 1,100-person waitlist. CANN calls for transparency, accountability, and stronger oversight in the 340B contract pharmacy system. | 04/24/2026 |
CANN Statement on Maryland PDAB's 'Plan of Action' (April 2026) | Public statement from Jen Laws, President & CEO of CANN, responding to the Maryland PDAB's mixed Jardiance and Farxiga decisions, and urging state leadership to require demonstrated patient access protections before policies are finalized. | 04/22/2026 |
CANN CEO Response to Industry Critiques of 340B Analysis | CANN CEO's response defending patient advocacy analysis of 340B program abuses against industry consultant critiques, asserting CANN speaks from lived patient experience while critics profit from the program. | 02/11/2026 |
CANN Releases Policy Brief on State 340B Conflicts with Federal Reforms | Press release announcing CANN's policy brief detailing conflicts between state 340B mandate laws and proposed federal reform legislation including the ACCESS Act and SUSTAIN draft. | 02/03/2026 |
CANN Statement to Senate HELP Committee on 340B Reform | Statement urging the Senate HELP Committee to prioritize patient-centered 340B reforms, highlighting PBM profiteering concerns and criticizing the absence of patient representation on witness panels. | 10/21/2025 |
CANN Statement on California SB 144: ADAP Rebate Fund Diversion | Statement opposing California SB 144 proposing $20 million diversion from ADAP rebate fund, asserting this violates Ryan White statutory requirements protecting HIV-specific program dollars. | 09/17/2025 |
Document Library
Document Title | Document Summary | Publication Date | Content Type |
|---|---|---|---|
340B Case Study: UC Health Poudre Valley Hospital | CANN's 340B case study on UC Health Poudre Valley Hospital finds it holds Colorado's highest hospital profit margin (33% in 2024), the state's largest fair-share deficit (~$59M/year), and spends only 1% of net patient revenue on charity care — despite 340B DSH participation. | 09/22/2026 | Case Study |
CANN Public Comment: Maryland PDAB Upper Payment Limit Clarification (September 2026) | CANN urges the Maryland PDAB to clarify how upper payment limits will avoid financial harm to pharmacies under COMAR 14.01.06.02, and opposes any reduction to the 60-day public comment period for drug cost review studies. | 09/22/2026 | Public Comment |
CANN Public Comment: Washington PDAB Ongoing Review Concerns (September 2026) | CANN urges the Washington PDAB to address process and data concerns in its ongoing drug review cycle, arguing that upper payment limits are ineffective affordability tools that risk adverse outcomes for patients, pharmacies, and 340B-covered entities. | 09/14/2026 | Public Comment |
CANN Public Comment: FDA Advisory Committee on GRAIL Galleri Multi-Cancer Early Detection Test (September 2026) | CANN urges the FDA Advisory Committee to grant full consideration and Premarket Approval to GRAIL's Galleri multi-cancer early detection test, highlighting the disproportionate cancer burden on people with HIV/AIDS, including anal cancer (20–25x higher risk), non-Hodgkin lymphoma, and cervical cancer. | 09/08/2026 | Public Comment |
CANN Public Comment: Senate HELP Committee 340B Drug Pricing Integrity and Affordability for Patients Act Discussion Draft (August 2026) | CANN urges the Senate HELP Committee to strengthen the 340B Drug Pricing Integrity and Affordability for Patients Act draft by requiring measurable patient outcomes, tightening 318 sub-grantee oversight, limiting contract pharmacy fees, expanding transparency reporting to all covered entities, and mandating patient savings disclosures. | 08/28/2026 | Public Comment |
CANN Statement on Introduction of the SUSTAIN 340B Act (August 2026) | CANN's CEO Jen Laws and 340B Policy Director Kalvin Pugh respond to the SUSTAIN 340B Act, criticizing its data clearinghouse user-fee model and failure to center patient interests, while praising its child site provisions as the strongest element of current federal 340B reform proposals. | 08/05/2026 | Press Release |
CANN Statement on HRSA's Revised 340B Rebate Model Pilot Program (August 2026) | Jen Laws, President & CEO of CANN, responds to HRSA's revised 340B Rebate Model Pilot Program, arguing it incentivizes covered entity compliance, addresses duplicate discounts, and moves HRSA toward active oversight — drawing on ADAP rebate model experience. | 08/04/2026 | Press Release |
CANN Statement on the Introduction of the SECURE 340B Act (July 2026) | Jen Laws, President & CEO of CANN, responds to the SECURE 340B Act, supporting patient benefit and transparency provisions while opposing the proposed clearinghouse in favor of a rebate model and calling for a clearer patient definition and child site language. | 07/06/2026 | Press Release |
CANN Statement on Minnesota Department of Health 340B Covered Entity Report (June 2026) | Jen Laws responds to Minnesota's February 2026 340B Covered Entity Report, finding MN covered entities earned $1.34 billion in net 340B revenue in 2024 — more than double 2023 — while safety-net clinics received less than 1%, calling for federal oversight to match the scale of the problem. | 06/16/2026 | Press Release |
CANN Public Comment: Biosimilar Red Tape Elimination Act (S. 1954) — Request to Preserve State Frameworks (June 2026) | CANN opposes S. 1954 as drafted, arguing that automatic biosimilar interchangeability deeming undermines the FDA-backed standard on which all 51 state pharmacy substitution frameworks rely, and urges the Senate HELP Committee to add a rule-of-construction provision preserving state biosimilar substitution authority before the June 17, 2026 markup. | 06/16/2026 | Public Comment |
CANN Public Comment: Washington PDAB UPL Rulemaking Draft (June 2026) | CANN submits comments on Washington's proposed UPL rulemaking (WAC 182-52-0010 and 182-52-0100), raising concerns about vague definitions of "excess costs," conflicting UPL scope language, inconsistent methodology standards, and appeals processes that disrupt the physician-patient relationship. | 06/16/2026 | Public Comment |
CANN Public Comment: 340B Rebate Model — House Appropriations Committee (June 2026) | CANN supports a rebate-based model for 340B transactions, arguing it enhances transparency, reduces duplicate discounts and diversion, and improves program integrity, while citing ADAPs as a proven "Gold Standard" and pushing back on DSH-system concerns. | 06/09/2026 | Public Comment |
CANN Written Comment: Maryland PDAB Cost Review Study Process Revisions (June 2026) | Comment to the Maryland PDAB on proposed amendments to COMAR 14.01.04 Cost Review Study Process, addressing the MCDB ERISA data blind spot, MDPN/IRA inclusion criteria, the risk that foreign data introduces QALY-based methods prohibited by the ADA, and the need for greater patient-centered focus. | 06/01/2026 | Public Comment |
CANN Written Comment: Maryland PDAB Ongoing Board Developments (May 2026) | Written comment to the Maryland PDAB on patient outreach concerns, the Board's mixed Farxiga (no UPL) and Jardiance (proposed UPL) decisions, and the moral and ethical concerns of testing UPL implementation on state mental health facilities and university health plans. | 05/12/2026 | Public Comment |
CANN Public Comment: Colorado PDAB Ongoing Board Activity (May 2026) | CANN raises questions about Colorado's PDAB ongoing board activity, focusing on HB23-1225 drug eligibility thresholds, the effectiveness of upper payment limits for patient out-of-pocket affordability, formulary protection gaps, and patient engagement via the PDAAC toolkit and Community Partner Network. | 05/11/2026 | Public Comment |
CANN Statement on Iowa's $22 Million 340B Contract Pharmacy Scandal (April 2026) | Jen Laws responds to Iowa's ADAP crisis caused by NuCara Specialty Pharmacy withholding $22M in 340B savings, forcing a 1,100-person waitlist. CANN calls for transparency, accountability, and stronger oversight in the 340B contract pharmacy system. | 04/24/2026 | Press Release |
CANN Statement on Maryland PDAB's 'Plan of Action' (April 2026) | Public statement from Jen Laws, President & CEO of CANN, responding to the Maryland PDAB's mixed Jardiance and Farxiga decisions, and urging state leadership to require demonstrated patient access protections before policies are finalized. | 04/22/2026 | Public Comment,Press Release |
CANN Public Comment: Louisiana PDAB SB401 — Oppose (March 2026) | CANN urges Louisiana's Senate Health and Welfare Committee to oppose SB401, which would create a Prescription Drug Affordability Board, arguing PDABs in 11 states have saved no money, exclude patient voices, discriminate against specialty medications, and harm 340B providers via upper payment limits. | 03/23/2026 | Public Comment |
CANN Public Comment: Oregon PDAB March 2026 | Comment addressing Oregon PDAB's March 2026 meeting on orphan drug interpretation and support for rebate pass-through affordability solutions. | 03/01/2026 | Public Comment |
CANN Written Comment: Maryland PDAB March 2026 | Written comment addressing Maryland PDAB's March 2026 meeting on implementation concerns missing baseline data and need for non-UPL affordability solutions. | 03/01/2026 | Public Comment |
Showing 1–20 of 500 documents
bottom of page